MAXONA Pharmaceuticals, a privately held, Malvern, Pennsylvania-based clinical-stage drug developer, has dosed the first patient in its Phase 2 trial of MAX-001, an investigational non-opioid treatment for acute pain, the company announced on November 18, 2026. The trial (NCT07937657) is testing MAX-001 in patients recovering from wisdom tooth removal.
“The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have repeatedly highlighted the critical necessity of expanding non-pharmacologic and non-opioid pharmacologic treatments to manage acute and chronic pain while reducing opioid misuse. MAXONA was founded to address the urgent need through the development of MAX-001,” said Shawn Fatholahi, President and CEO of MAXONA Pharmaceuticals.
Inside the Phase 2 Trial
The randomized, double-blind, placebo-controlled trial will test several doses of MAX-001 for safety and efficacy in 276 patients having both lower impacted wisdom teeth removed. It uses the Dental Impaction Pain Model, a common approach for testing how well experimental painkillers relieve moderate-to-severe pain after surgery.
The U.S.-based study is being led by Dr. Todd Bertoch, Chief Medical Officer of CenExel Medical Research.
“DIPM offers high assay sensitivity because the patient population is relatively homogeneous, allows researchers to measure onset, peak effect, and duration of pain relief, and can be pre-selected via X-rays to target specific intensity levels of postsurgical pain,” Dr. Bertoch said.
In March 2025, MAXONA reported Phase 1 results showing MAX-001 was well tolerated, with no serious or severe adverse events reported.
About MAX-001
MAX-001 is an investigational extended-release formulation of nefopam, a non-opioid, non-NSAID pain reliever. Nefopam is prescribed for pain outside the United States but is not approved in the U.S. MAX-001 is designed to provide both rapid onset and extended pain relief. It works by blocking the reuptake of three neurotransmitters: norepinephrine, serotonin, and dopamine. MAXONA is developing it as a new molecular entity for both acute and chronic pain.
About MAXONA Pharmaceuticals
MAXONA develops treatments for acute and chronic pain that avoid the side effects and addiction risks associated with opioids and NSAIDs. Its leadership team brings expertise in neuroscience, drug development, formulation and delivery technology, clinical trial design, and pharmacology.
Cautionary Statement Regarding Forward Looking Statements
This release may contain “forward-looking statements”. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the company. The company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.
Source: MAXONA Pharmaceuticals, https://www.prnewswire.com/news-releases/maxona-pharmaceuticals-announces-first-patient-dosed-in-max-001-clinical-trial-for-acute-pain-302943146.html on November 18, 2026. Republished with credit to the original author. Read the original article.